Table 5 |
||||
|
Peak and mean uNGAL concentrations in survivors and nonsurvivors, by pRIFLEmax AKI strata |
||||
|
Measurement (ng/mg creatinine) |
Group (numbers of patients: survivors/nonsurvivors) |
|||
|
|
||||
|
Control (31/3) |
pRIFLEmax R (46/4) |
pRIFLEmax I (25/6) |
pRIFLEmax F (18/7) |
|
|
|
||||
|
Peak uNGALa |
||||
|
Survivors |
0.6 ± 1.8/0.1 (0.4) |
0.9 ± 1.4/0.4 (1.2) |
2.4 ± 3.5/0.8 (2.0) |
4.1 ± 3.7/2.7 (5.5) |
|
Nonsurvivors |
0.4 ± 0.3/0.2 (0.5) |
1.8 ± 2.7/0.7 (3.2) |
2.7 ± 5.0/0.9 (1.0) |
2.8 ± 4.0/1.5 (1.8) |
|
Mean uNGALa,b |
||||
|
Survivors |
0.4 ± 1.3/0.1 (0.2) |
0.6 ± 0.8/0.3 (0.7) |
1.6 ± 2.5/0.5 (1.8) |
3.1 ± 3.1/2.2 (4.2) |
|
Nonsurvivors |
0.3± 0.2/0.2 (0.4) |
1.1 ± 1.5/0.6 (2.1) |
1.8 ± 3.0/1.0 (1.1) |
1.9 ± 2.6/1.1 (1.1) |
|
|
||||
|
Values are expressed as mean ± standard deviation/median (interquartile range). aPeak and mean urine neutrophil gelatinase-associated lipocalin (uNGAL) concentrations were not statistically significantly different between survivors and nonsurvivors in any of the pRIFLE strata (P > 0.05, Mann-Whitney test). bMean uNGAL refers to the mean of all 4 urine specimens collected for each patient. pRIFLEmax, the worst pRIFLE stratum attained; pRIFLE, pediatric modified Risk, Injury, Failure, Loss, End Stage Kidney Disease. |
||||
|
Zappitelli et al. Critical Care 2007 11:R84 doi:10.1186/cc6089 |
||||
